Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) EBT (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed EBT for 16 consecutive years, with $5.1 million as the latest value for Q4 2025.

  • Quarterly EBT rose 124.13% to $5.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $19.6 million through Dec 2025, up 1526.1% year-over-year, with the annual reading at $19.6 million for FY2025, 1526.1% up from the prior year.
  • EBT for Q4 2025 was $5.1 million at Gyre Therapeutics, down from $7.6 million in the prior quarter.
  • The five-year high for EBT was $51.6 million in Q2 2022, with the low at -$100.3 million in Q4 2023.
  • Average EBT over 5 years is -$6.7 million, with a median of $3.1 million recorded in 2024.
  • The sharpest move saw EBT plummeted 453.2% in 2021, then soared 359.42% in 2022.
  • Over 5 years, EBT stood at -$20.4 million in 2021, then decreased by 11.84% to -$22.8 million in 2022, then tumbled by 339.82% to -$100.3 million in 2023, then soared by 78.82% to -$21.2 million in 2024, then soared by 124.13% to $5.1 million in 2025.
  • According to Business Quant data, EBT over the past three periods came in at $5.1 million, $7.6 million, and $2.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.